2018 대한부정맥학회 비판막성 심방세동 환자의 뇌졸중 예방 지침

키워드

참고문헌 (163)

1. Lip GY, "Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation", Chest, 137, pp.263~272 (2010)[DOI]
2. Camm AJ, "Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)", Europace, 12, pp.1360~1420 (2010)[DOI]
3. Kirchhof P, "Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology", European Heart Rhythm Association, American Heart Association, pp.Heart Rhythm Society, and the Canadian Cardiovascular Society, Eur Heart J[DOI]
4. Lip GY, "Stroke prevention in atrial fibrillation: a systematic review", JAMA, 313, pp.1950~1962 (2015)[DOI]
5. Mason PK, "Impact of the CHA2DS2-VASc score on anticoagulation recommendations for atrial fibrillation", Am J Med, 125, pp.603.e1~603.e6 (2012)[DOI]
6. Kim TH, "CHA2DS2-VASc score for identifying truly low-risk atrial fibrillation for stroke: a Korean nationwide cohort study", Stroke, 48, pp.2984~2990 (2017)[DOI]
7. Kang SH, "Risk of ischemic stroke in patients with non-valvular atrial fibrillation not receiving oral anticoagulants-Korean nationwide population-based Study", Circ J, 81, pp.1158~1164 (2017)[DOI]
8. , vascular disease, age 65-74, female) for stroke in asian patients with atrial fibrillation: a Korean nationwide sample cohort study, "Stroke", 2017, 1524~1530, 10.1161[DOI]
9. Lee SR, "Trends in the incidence and prevalence of atrial fibrillation and estimated thromboembolic risk using the CHA2DS2-VASc score in the entire Korean population", Int J Cardiol, 236, pp.226~231 (2017)[DOI]
10. Olesen JB, "Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study", BMJ, 342, pp.d124~ (2011)[DOI]
11. Chao TF, "Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?", J Am Coll Cardiol, 65, pp.635~642 (2015)[DOI]
12. Lip GY, "Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score", J Am Coll Cardiol, 65, pp.1385~1394 (2015)[DOI]
13. Fauchier L, "Oral anticoagulation and the risk of stroke or death in patients with atrial fibrillation and one additional stroke risk factor: The Loire Valley atrial fibrillation project", Chest, 149, pp.960~968 (2016)[DOI]
14. Joundi RA, "Ischemic stroke risk in patients with atrial fibrillation and CHA2DS2-VASc score of 1: systematic review and meta-analysis", Stroke, 47, pp.1364~1367 (2016)[DOI]
15. Friberg L, "Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1", J Am Coll Cardiol, 65, pp.225~232 (2015)[DOI]
16. Allan V, "Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care", Heart, 103, pp.210~218 (2017)[DOI]
17. Lip GY, "Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy", Thromb Haemost, 114, pp.826~834 (2015)[DOI]
18. Mikkelsen AP, "Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study", J Thromb Haemost, 10, pp.1745~1751 (2012)[DOI]
19. Wagstaff AJ, "Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis", QJM, 107, pp.955~967 (2014)[DOI]
20. Eckman MH, "Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation", Circ Cardiovasc Qual Outcomes, 4, pp.14~21 (2011)[DOI]
21. Overvad TF, "Treatment thresholds for stroke prevention in atrial fibrillation: observations on the CHA2DS2-VASc score", Eur Heart J Cardiovasc Pharmacother, 3, pp.37~41 (2017)[DOI]
22. Hijazi Z, "The ABC (age, biomarkers, clinical history) stroke risk score: a biomarkerbased risk score for predicting stroke in atrial fibrillation", Eur Heart J, 37, pp.1582~1590 (2016)[DOI]
23. Lee JM, "Additional value of left atrial appendage geometry and hemodynamics when considering anticoagulation strategy in patients with atrial fibrillation with low <TEX>$CHA_{2}DS_{2}$<", TEX>-VASc scores, 2017, pp.14, 1297~1301
24. Szekely P, "Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease", Br Med J, 1, pp.1209~1212 (1964)[DOI]
25. Olesen KH, "The natural history of 271 patients with mitral stenosis under medical treatment", Br Heart J, 24, pp.349~357 (1962)[DOI]
26. Perez-Gomez F, "Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study", J Am Coll Cardiol, 44, pp.1557~1566 (2004)[DOI]
27. Rowe JC, "The course of mitral stenosis without surgery: ten- and twenty-year perspectives", Ann Intern Med, 52, pp.741~749 (1960)[DOI]
28. Wilson JK, "The natural history of mitral stenosis", Can Med Assoc J, 71, pp.323~331 (1954)
29. Cannegieter SC, "Warfarin and aspirin after heart-valve replacement", N Engl J Med, 330, pp.507~508 (1994)
30. Chiang CW, "Predictors of systemic embolism in patients with mitral stenosis. A prospective study", Ann Intern Med, 128, pp.885~889 (1998)[DOI]
31. Eikelboom JW, "Dabigatran versus warfarin in patients with mechanical heart valves", N Engl J Med, 369, pp.1206~1214 (2013)[DOI]
32. Breithardt G, "Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial", Eur Heart J, 35, pp.3377~3385 (2014)[DOI]
33. Avezum A, "Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial", Circulation, 132, pp.624~632 (2015)[DOI]
34. Carnicelli AP, "Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves", Circulation, 135, pp.1273~1275 (2017)[DOI]
35. Fang MC, "A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study", J Am Coll Cardiol, 58, pp.395~401 (2011)[DOI]
36. Gage BF, "Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)", Am Heart J, 151, pp.713~719 (2006)[DOI]
37. Hijazi Z, "The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study", Lancet, 387, pp.2302~2311 (2016)[DOI]
38. O'Brien EC, "The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation", Eur Heart J, 36, pp.3258~3264 (2015)
39. Pisters R, "A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation:the Euro Heart Survey", Chest, 138, pp.1093~1100 (2010)[DOI]
40. Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361, pp.1139~1151 (2009)[DOI]
41. Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369, pp.2093~2104 (2013)[DOI]
42. Granger CB, "Apixaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 365, pp.981~992 (2011)[DOI]
43. Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)[DOI]
44. Connolly SJ, "Newly identified events in the RE-LY trial", N Engl J Med, 363, pp.1875~1876 (2010)[DOI]
45. Sjogren V, "Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula", Thromb Haemost, 113, pp.1370~1377 (2015)[DOI]
46. Connolly SJ, "Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range", Circulation, 118, pp.2029~2037 (2008)[DOI]
47. Wan Y, "Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review", Circ Cardiovasc Qual Outcomes, 1, pp.84~91 (2008)[DOI]
48. Morgan CL, "Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control", Thromb Res, 124, pp.37~41 (2009)[DOI]
49. Gallagher AM, "Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients", Thromb Haemost, 106, pp.968~977 (2011)[DOI]
50. De Caterina R, "Vitamin K antagonists in heart disease: current status and perspectives (section III). position paper of the ESC Working Group on thrombosis--task force on anticoagulants in heart disease", Thromb Haemost, 110, pp.1087~1107 (2013)[DOI]
51. Oldgren J, "placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial", Eur Heart J, 32, pp.2781~2789 (2011)[DOI]
52. Hart RG, "Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation", Ann Intern Med, 146, pp.857~867 (2007)[DOI]
53. Wallentin L, "Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial", Lancet, 376, pp.975~983 (2010)[DOI]
54. Olesen JB, "Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study", Thromb Haemost, 106, pp.739~749 (2011)[DOI]
55. Dans AL, "Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial", Circulation, 127, pp.634~640 (2013)[DOI]
56. Sjalander S, "Atrial fibrillation patients do not benefit from acetylsalicylic acid", Europace, 16, pp.631~638 (2014)[DOI]
57. Raunso J, "Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation", Eur Heart J, 33, pp.1886~1892 (2012)[DOI]
58. Graham DJ, "Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation", Circulation, 131, pp.157~164 (2015)[DOI]
59. Choi WS, "Optimal international normalized ratio for warfarin therapy in elderly Korean patients with non-valvular atrial fibrillation", Int J Arrhythm, 17, pp.167~173 (2016)[DOI]
60. Apostolakis S, "Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score", Chest, 144, pp.1555~1563 (2013)[DOI]
61. Gallego P, "SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation", Am J Med, 127, pp.1083~1088 (2014)[DOI]
62. Lip GYH, "Relationship of the SAMe-TT2R2 score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation", Chest, 146, pp.719~726 (2014)[DOI]
63. Larsen TB, "Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study", BMJ, 353, pp.i3189~ (2016)
64. Cha MJ, "Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation", Stroke, 48, pp.3040~3048 (2017)[DOI]
65. Connolly SJ, "Apixaban in patients with atrial fibrillation", N Engl J Med, 364, pp.806~817 (2011)[DOI]
66. Olesen JB, "Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013", Europace, 17, pp.187~193 (2015)[DOI]
67. Choi EJ, "Inadequate stroke prevention in Korean atrial fibrillation patients in the post-warfarin era", Int J Cardiol, 220, pp.647~652 (2016)[DOI]
68. Hylek EM, "Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes", J Am Coll Cardiol, 63, pp.2141~2147 (2014)[DOI]
69. Proietti M, "Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis", Stroke, 49, pp.98~106 (2018)[DOI]
70. 정보영, "Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients", Korean Circulation Journal, 47(6), pp.833~841 (2017), 대한심장학회[DOI]
71. Chan YH, "Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation", J Am Coll Cardiol, 68, pp.1389~1401 (2016)[DOI]
72. Pollack CV, "Idarucizumab for dabigatran reversal-full cohort analysis", N Engl J Med, 377, pp.431~441 (2017)[DOI]
73. Ruff CT, "Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial", Lancet, 385, pp.2288~2295 (2015)[DOI]
74. Beyer-Westendorf J, "Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the dresden NOAC registry", Blood, 124, pp.955~962 (2014)[DOI]
75. Camm AJ, "XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation", Eur Heart J, 37, pp.1145~1153 (2016)[DOI]
76. Ruff CT, "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials", Lancet, 383, pp.955~962 (2014)[DOI]
77. Piccini JP, "Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial", J Am Heart Assoc, 3, pp.e000521~ (2014)[DOI]
78. Fox KA, "Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment", Eur Heart J, 32, pp.2387~2394 (2011)[DOI]
79. Eikelboom JW, "Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease", J Stroke Cerebrovasc Dis, 21, pp.429~435 (2012)[DOI]
80. Hohnloser SH, "Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial", Eur Heart J, 33, pp.2821~2830 (2012)[DOI]
81. Hijazi Z, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (randomized evaluation of long-term anticoagulation therapy) trial analysis", Circulation, 129, pp.961~970 (2014)[DOI]
82. Hart RG, "Warfarin in atrial fibrillation patients with moderate chronic kidney disease", Clin J Am Soc Nephrol, 6, pp.2599~2604 (2011)[DOI]
83. Friberg L, "Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish atrial fibrillation cohort study", Eur Heart J, 36, pp.297~306 (2015)[DOI]
84. Jun M, "The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study", BMJ, 350, pp.h246~ (2015)[DOI]
85. Del-Carpio Munoz F, "Meta-analysis of renal function on the safety and efficacy of novel oral anticoagulants for atrial fibrillation", Am J Cardiol, 117, pp.69~75 (2016)[DOI]
86. Heidbuchel H, "Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation", Europace, 17, pp.1467~1507 (2015)[DOI]
87. Zimmerman D, "Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis", Nephrol Dial Transplant, 27, pp.3816~3822 (2012)[DOI]
88. Wizemann V, "Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy", Kidney Int, 77, pp.1098~1106 (2010)[DOI]
89. Chan KE, "Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation", J Am Soc Nephrol, 20, pp.2223~2233 (2009)[DOI]
90. Winkelmayer WC, "Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation", Clin J Am Soc Nephrol, 6, pp.2662~2668 (2011)[DOI]
91. Schwartzenberg S, "The quandary of oral anticoagulation in patients with atrial fibrillation and chronic kidney disease", Am J Cardiol, 117, pp.477~482 (2016)[DOI]
92. Shah M, "Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis", Circulation, 129, pp.1196~1203 (2014)[DOI]
93. Bonde AN, "Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study", J Am Coll Cardiol, 64, pp.2471~2482 (2014)[DOI]
94. ACTIVE Writing Group of the ACTIVE Investigators, "Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial", Lancet, 367, pp.1903~1912 (2006)[DOI]
95. ACTIVE Investigators, "Effect of clopidogrel added to aspirin in patients with atrial fibrillation", N Engl J Med, 360, pp.2066~2078 (2009)[DOI]
96. Mant J, "Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial", Lancet, 370, pp.493~503 (2007)[DOI]
97. van Walraven C, "Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators", Stroke, 40, pp.1410~1416 (2009)[DOI]
98. Budera P, "Comparison of cardiac surgery with left atrial surgical ablation vs. cardiac surgery without atrial ablation in patients with coronary and", or valvular heart disease plus atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study, 2012, pp.33, 2644~2652
99. Healey JS, "Left atrial appendage occlusion study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke", Am Heart J, 150, pp.288~293 (2005)[DOI]
100. Holmes DR, "Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial", J Am Coll Cardiol, 64, pp.1~12 (2014)[DOI]
101. Holmes DR Jr, "Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis", J Am Coll Cardiol, 65, pp.2614~2623 (2015)[DOI]
102. Reddy VY, "Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (watchman left atrial appendage system for embolic protection in patients with atrial fibrillation) trial", Circulation, 127, pp.720~729 (2013)[DOI]
103. Tsai YC, "Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis", Eur J Cardiothorac Surg, 47, pp.847~854 (2015)[DOI]
104. Boersma LV, "Atrial fibrillation catheter ablation versus surgical ablation treatment (FAST): a 2-center randomized clinical trial", Circulation, 125, pp.23~30 (2012)[DOI]
105. Bajaj NS, "Percutaneous left atrial appendage occlusion for stroke prophylaxis in nonvalvular atrial fibrillation: a systematic review and analysis of observational studies", JACC Cardiovasc Interv, 7, pp.296~304 (2014)[DOI]
106. Lewalter T, "Ischaemic stroke prevention in patients with atrial fibrillation and high bleeding risk: opportunities and challenges for percutaneous left atrial appendage occlusion", Europace, 16, pp.626~630 (2014)[DOI]
107. Meier B, "EHRA", EAPCI expert consensus statement on catheter-based left atrial appendage occlusion, 2014, pp.16, 1397~1416
108. Kim JS, "Left atrial appendage occlusion in non-valvular atrial fibrillation in a Korean multi-center registry", Circ J, 80, pp.1123~1130 (2016)[DOI]
109. Holmes DR, "Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial", Lancet, 374, pp.534~542 (2009)[DOI]
110. Reddy VY, "Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial", JAMA, 312, pp.1988~1998 (2014)[DOI]
111. Santoro G, "Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER cardiac plug", EuroIntervention, 11, pp.1188~1194 (2016)[DOI]
112. Badheka AO, "Utilization and adverse outcomes of percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation in the United States: influence of hospital volume", Circ Arrhythm Electrophysiol, 8, pp.42~48 (2015)[DOI]
113. Pison L, "Left atrial appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey", Europace, 17, pp.642~646 (2015)[DOI]
114. Price MJ, "Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium", J Am Coll Cardiol, 64, pp.565~572 (2014)[DOI]
115. Boersma LV, "Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry", Eur Heart J, 37, pp.2465~2474 (2016)[DOI]
116. Kuramatsu JB, "Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage", JAMA, 313, pp.824~836 (2015)[DOI]
117. Casu G, "ANMCO", AIAC, SIC, pp.SICCH Consensus Document: percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients: indications, patient selection, staff skills, organisation, and training, Eur Heart J Suppl[DOI]
118. Katz ES, "Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiograhic study", J Am Coll Cardiol, 36, pp.468~471 (2000)[DOI]
119. Whitlock R, "Rationale and design of the left atrial appendage occlusion study (LAAOS) III", Ann Cardiothorac Surg, 3, pp.45~54 (2014)
120. Aryana A, "Association between incomplete surgical ligation of left atrial appendage and stroke and systemic embolization", Heart Rhythm, 12, pp.1431~1437 (2015)[DOI]
121. Xian Y, "Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator", JAMA, 307, pp.2600~2608 (2012)
122. Mazya MV, "Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin", Ann Neurol, 74, pp.266~274 (2013)[DOI]
123. Park YA, "Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage", Heart Rhythm, 13, pp.1794~1802 (2016)[DOI]
124. Felmeden DC, "Antithrombotic therapy in hypertension: a cochrane systematic review", J Hum Hypertens, 19, pp.185~196 (2005)[DOI]
125. Eikelboom JW, "Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial", Circulation, 123, pp.2363~2372 (2011)[DOI]
126. Chang HY, "Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study", BMJ, 350, pp.h1585~ (2015)[DOI]
127. Abraham NS, "Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study", BMJ, 350, pp.h1857~ (2015)[DOI]
128. Sharma M, "Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis", Circulation, 132, pp.194~204 (2015)[DOI]
129. Palareti G, "Bleeding with anticoagulation therapy-who is at risk, and how best to identify such patients", Thromb Haemost, 102, pp.268~278 (2009)[DOI]
130. Douketis JD, "Perioperative bridging anticoagulation in patients with atrial fibrillation", N Engl J Med, 373, pp.823~833 (2015)[DOI]
131. Kim TH, "Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non-valvular atrial fibrillation patients: a multicenter propensity-matched analysis", J Thromb Haemost, 13, pp.182~190 (2015)[DOI]
132. Roskell NS, "Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies", Europace, 15, pp.787~797 (2013)[DOI]
133. Hughes M, "Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review", QJM, 100, pp.599~607 (2007)[DOI]
134. Mancia G, "2013 ESH", ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), 2013, pp.34, 2159~2219
135. Goodman SG, "Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)", J Am Coll Cardiol, 63, pp.891~900 (2014)[DOI]
136. Nielsen PB, "Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study", BMJ, 356, pp.j510~ (2017)
137. Nielsen PB, "Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis", Clin Res Cardiol, 104, pp.418~429 (2015)[DOI]
138. Lee SJ, "Bleeding risk and major adverse events in patients with previous ulcer on oral anticoagulation therapy", Am J Cardiol, 110, pp.373~377 (2012)[DOI]
139. Lee SJ, "The safety and efficacy of vitamin K antagonist in atrial fibrillation patients with previous ulcer bleeding: Long-term results from a multicenter study", Medicine (Baltimore), 95, pp.e5467~ (2016)[DOI]
140. Bjorck F, "Outcomes in a warfarin-treated population with atrial fibrillation", JAMA Cardiol, 1, pp.172~180 (2016)[DOI]
141. Oh S, "Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: real-world data from the GARFIELD-AF registry", Int J Cardiol, 223, pp.543~547 (2016)[DOI]
142. Jacobs LG, "Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and", or early-stage dementia: a single-center, retrospective, observational study, 2009, pp.7, 159~166
143. Banerjee A, "Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley atrial fibrillation project", Am J Med, 127, pp.972~978 (2014)[DOI]
144. van Schie RM, "Genotypeguided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design", Pharmacogenomics, 10, pp.1687~1695 (2009)[DOI]
145. International Warfarin Pharmacogenetics Consortium, "Estimation of the warfarin dose with clinical and pharmacogenetic data", N Engl J Med, 360, pp.753~764 (2009)[DOI]
146. Schwarz UI, "Genetic determinants of response to warfarin during initial anticoagulation", N Engl J Med, 358, pp.999~1008 (2008)[DOI]
147. Tang T, "Genotype-guided dosing of coumarin anticoagulants: a meta-analysis of randomized controlled trials", J Cardiovasc Pharmacol Ther, 20, pp.387~394 (2015)[DOI]
148. Niessner A, "Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis", Eur Heart J, 38, pp.1710~1716 (2017)
149. Cuker A, "Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants", J Am Coll Cardiol, 64, pp.1128~1139 (2014)[DOI]
150. Hanley J, "Warfarin reversal", J Clin Pathol, 57, pp.1132~1139 (2004)[DOI]
151. Parry-Jones AR, "Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage", Ann Neurol, 78, pp.54~62 (2015)[DOI]
152. Goldstein JN, "Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial", Lancet, 385, pp.2077~2087 (2015)[DOI]
153. Pollack CV Jr, "Idarucizumab for dabigatran reversal", N Engl J Med, 373, pp.511~520 (2015)[DOI]
154. Siegal DM, "Andexanet alfa for the reversal of factor Xa inhibitor activity", N Engl J Med, 373, pp.2413~2424 (2015)[DOI]
155. Crowther M, "Antidotes for novel oral anticoagulants: current status and future potential", Arterioscler Thromb Vasc Biol, 35, pp.1736~1745 (2015)[DOI]
156. Staerk L, "Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: temporal trends 2011-2015 in Denmark", Sci Rep, 6, pp.31477~ (2016)[DOI]
157. Dewilde WJ, "Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial", Lancet, 381, pp.1107~1115 (2013)[DOI]
158. Braun OO, "Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome", Thromb Res, 135, pp.26~30 (2015)[DOI]
159. Sarafoff N, "Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation", J Am Coll Cardiol, 61, pp.2060~2066 (2013)[DOI]
160. Oldgren J, "New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis", Eur Heart J, 34, pp.1670~1680 (2013)[DOI]
161. Cannon CP, "Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation", N Engl J Med, 377, pp.1513~1524 (2017)[DOI]
162. Gibson CM, "Prevention of bleeding in patients with atrial fibrillation undergoing PCI", N Engl J Med, 375, pp.2423~2434 (2016)[DOI]
163. Vranckx P, "Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful Percutaneous Coronary Intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI Trial", Am Heart J, 196, pp.105~112 (2018)[DOI]

관련 논문AI추천